How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

29,491 results for

Intravenous Drug Abuse

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. 48-year-old Man with Fevers, Chest Pain, and a History of Substance Abuse Full Text available with Trip Pro

48-year-old Man with Fevers, Chest Pain, and a History of Substance Abuse A 48-year-old male with a history of intravenous (IV) drug use presented to the emergency department (ED) for an area of mild pain and erythema on his chest. He was then triaged to the urgent care, or fast track, area of the ED. He was well appearing with normal lab findings and vital signs, but his workup revealed mediastinitis with osteomyelitis of the manubrium and clavicles, a surgical emergency. His treatment course (...) included IV antibiotics and operative intervention with thoracic surgery. The patient looked too good to be sick, yet he had a life-threatening infection.

2018 Clinical Practice and Cases in Emergency Medicine

182. Evaluation of Doxazosin to Alter the Abuse of Oxycodone

Date : December 30, 2019 Estimated Study Completion Date : March 30, 2020 Resource links provided by the National Library of Medicine available for: Arms and Interventions Go to Arm Intervention/treatment Placebo Comparator: Doxazosin 0 mg (Placebo) Maintenance on a daily dose of oral doxazosin (0 mg) for 4 weeks. During this time subjects complete testing sessions (Self-administration, Cue session) assessing the abuse potential of intranasal oxycodone. Drug: Intranasal Oxycodone Under each (...) doxazosin maintenance condition the effects of intranasal oxycodone will be assessed in order to determine if doxazosin reduces dependent measures assessing its abuse potential. Other Name: Oxycodone HCl Behavioral: Cue Session During the cue exposure session participants are presented with neutral cues followed by drug-related cues. This procedure will allow the investigators to determine whether the study medication affects reactivity to drug-related cues. Active Comparator: Doxazosin 16 mg

2018 Clinical Trials

183. Nicotine Delivery Rate and Its Abuse Potential: Impact of Menthol

Purpose: Health Services Research Official Title: Nicotine Delivery Rate and Its Abuse Potential: Impact of Menthol Estimated Study Start Date : December 1, 2018 Estimated Primary Completion Date : August 1, 2020 Estimated Study Completion Date : December 1, 2020 Resource links provided by the National Library of Medicine available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: nicotine saline infusion 0.00mcg/kg/s 0.00 mcg/kg/s The day order will be randomized per day Drug (...) an IV infusion of either saline or 1 mg nicotine at rapid, moderate or slow infusion rates (nicotine at 0.24,0.096, 0.048 and 0.024, mcg per kg body weight per sec). The infusion conditions for each experimental session will be determined in random order. Aim 1 is to establish a dose-effect curve for positive subjective effects (drug liking and good drug effects) and alleviation of smoking urges, as a function of nicotine delivery rate in menthol and non-menthol cigarette preferring smokers Aim 2

2018 Clinical Trials

184. Evaluation of the Abuse Liability of Very Low Nicotine (VLN) Cigarettes

. Clinically significant abnormal findings on the vital signs, physical examination (including oral exam), medical history, or clinical laboratory results, in the opinion of an investigator. Positive serology test results for human immunodeficiency virus (HIV-1/HIV-2) Antibodies, hepatitis B surface antigen (HbsAg), or hepatitis C Antibody (HCVAb). An acute illness (e.g., upper respiratory infection, viral infection) requiring treatment within 2 weeks prior to Day -1 (check-in). Drug or alcohol abuse (...) : 22nd Century Group, Inc. Collaborator: Vince & Associates Clinical Research, Inc. Information provided by (Responsible Party): 22nd Century Group, Inc. Study Details Study Description Go to Brief Summary: This study is designed to evaluate the abuse liability of very low nicotine cigarettes compared to nicotine gum and usual brand cigarettes Condition or disease Intervention/treatment Phase Tobacco Use Other: VLN cigarettes (A) Other: Usual Brand Cigarettes (B) Drug: Nicotine gum (C) Phase 1

2018 Clinical Trials

185. Evaluation of Abuse Liability of Very Low Nicotine (VLN) Mentholated Cigarettes

infection) requiring treatment within 2 weeks prior to Day -1 (check-in). Drug or alcohol abuse or dependence within the 24 months prior to Screening (except nicotine), as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th edition text revision (DSM-IV-TR), or any self-reported dependence or "addiction" within the subject's lifetime (except nicotine or caffeine). Subjects who have ever been in treatment for substance use disorder(s) or who are currently Positive urine drug screen (...) & Associates Clinical Research, Inc. Information provided by (Responsible Party): 22nd Century Group, Inc. Study Details Study Description Go to Brief Summary: This study is designed to evaluate the abuse liability of mentholated very low nicotine cigarettes compared to nicotine gum and usual brand cigarettes. Condition or disease Intervention/treatment Phase Tobacco Use Other: VLN menthol cigarettes (A) Other: Usual Brand Menthol Cigarettes (B) Drug: Nicotine gum (C) Phase 1 Detailed Description

2018 Clinical Trials

186. Trial of the Rapid Antisuicidal Effects of Intranasal Ketamine in Comorbid Depression and Alcohol Abuse

Effects of Intranasal Ketamine in Comorbid Depression and Alcohol Abuse Actual Study Start Date : May 1, 2018 Estimated Primary Completion Date : January 1, 2019 Estimated Study Completion Date : March 1, 2019 Resource links provided by the National Library of Medicine related topics: related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Intranasal ketamine Intranasal ketamine Drug: Intranasal ketamine Intranasal ketamine will be prepared as 100mg/ml (...) seizures or significant abnormal laboratory tests (liver function test (LFT) 3 times higher than normal). Prior diagnosis of a DSM-IV-TR psychotic spectrum disorder, psychotic symptoms, or personality disorder. Currently under the acute effects of an illicit substance. Pregnant or nursing women. Subjects with a history of DSM-IV drug dependency or abuse (except for caffeine or nicotine dependence) within the preceding 3 months Contacts and Locations Go to Information from the National Library

2018 Clinical Trials

187. A Prenatal Mentalization-focused 4D Ultrasound and a Pregnancy Diary Intervention for Substance-abusing Women

abuse documented in the hospital medical records (intoxications, urine screening results, marks indicating intravenous substance abuse): The more findings, the worse the outcome. Prenatal anxiety symptoms post-intervention at 35 gestational weeks [ Time Frame: Post-intervention at 35 gestational weeks ] Assessment of prenatal anxiety symptoms with The State Section of The State-Trait Anxiety Inventory (STAI): theoretical range of total scale is 20-80points (minimum and maximum scores), and lower (...) : No Criteria Inclusion Criteria: Pregnant women referred to the hospital maternity outpatient clinic from primary health care due to substance abuse were recruited to participate in a randomized and controlled study. The subjects were referred from primary health care due to: documented or self-reported illicit drug use, misuse of prescription medication or alcohol within three years prior to or during this pregnancy, and/or sum score ≥ 3 points on TWEAK alcohol screening (Russell, 1994). The inclusion

2018 Clinical Trials

188. A Trial to Evaluate the Abuse Potential of 3 Doses of GRT6005 in Adult Non-dependent Recreational Opioid Users

to placebo (trial validation), to evaluate the safety and tolerability of single doses of cebranopadol (200, 400, and 800 micrograms), and to evaluate pharmacokinetics (PK) of cebranopadol and optionally some of its metabolites. Condition or disease Intervention/treatment Phase Abuse, Drug Drug: Cebranopadol 100 micrograms Drug: Cebranopadol 400 micrograms Drug: Hydromorphone hydrochloride 4 milligrams Drug: Placebo matching hydromorphone Drug: Placebo matching cebranopadol Phase 1 Detailed Description (...) dose of hydromorphone immediate-release (IR) 12 milligrams (mg) and placebo in a double-blinded, randomized crossover manner to ensure that they could discriminate between an active drug and placebo and could tolerate hydromorphone IR 12 mg. After a washout phase of at least 3 days, participants could continue with the Treatment Phase. In the Treatment Phase, each participant received single oral doses of the 7 different investigational medicinal products (IMPs) (Treatment A to Treatment G) in 7

2018 Clinical Trials

189. The Effectiveness of Incarceration?Based Drug Treatment on Criminal Behavior: A Systematic Review Full Text available with Trip Pro

found that 36% were dependent on drugs and another 18% abused drugs ( ). When alcohol was included in these estimates, 68% of jail inmates were found to be either dependent (45%) or abusers (23%). Likewise, a 2004 survey of State and Federal prison inmates, found that 53% of State and 45% of Federal prisoners met the DSM‐IV criteria for drug dependence or abuse ( ). In fact, it is estimated that about 40% of all Americans who clearly need drug treatment are under the supervision of the criminal (...) therapies, in which substance abuse and other common problems are discussed among peers in an effort to solve mutual issues. However, not all counseling programs rely on peer therapy; some counseling programs are individual‐based where the client and a clinician work together to remedy drug problems. And still other counseling programs include both group and individual counseling. Boot camps are modeled after military basic training. Inmates participate in rigorous exercise regimens, learn military

2012 Campbell Collaboration

190. Suboxone for Drug Detoxification: Clinical Effectiveness and Guidelines

, Cockayne L. Medically assisted recovery from opiate dependence within the context of the UK drug strategy: methadone and Suboxone (buprenorphine-naloxone) patients compared. J Subst Abuse Treat. 2012 Jun 15. Epub ahead of print. PubMed: PM22703715 Suboxone for Drug Detoxification 3 7. Steele A, Cunningham P. A comparison of Suboxone and clonidine treatment outcomes in opiate detoxification. Arch Psychiatr Nurs. 2012 Aug;26(4):316-23. PubMed: PM22835751 8. Rapeli P, Fabritius C, Alho H, Salaspuro M (...) /pmc/articles/PMC2610690 PubMed: PM18984887 5. Ling W, Amass L, Shoptaw S, Annon JJ, Hillhouse M, Babcock D, et al. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction [Internet]. 2005 Aug [cited 2012 Aug 16];100(8):1090-100. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1480367 PubMed: PM16042639 Non-Randomized Studies 6. Mckeganey N, Russell C

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review

191. Naloxone for Respiratory Depression in Patients with Drug or Addiction Issues: A Review of the Evidence on Safety and Guidelines

opioids can be used therapeutically, recreationally, and children may be unintentionally exposed to them. 1 Opioid addiction and abuse is a major medical and social problem all around the world. 1,2 The opioids exert their biologic effects through interactions with multiple opioid receptors (µ, d and ?). The µ-opioid receptor is attributed to respiratory depression - a main hazard of severe opioid overdose which is potentially fatal. 1,3-5 Opioid antagonists are commonly used as rescue medications (...) to reverse severe opioid-induced respiratory depression. 4,6 Naloxone is a non-selective, short-acting opioid receptor antagonist which acts on the µ-, d- and ?-opioid receptors. 2 It has been approved by Health Canada as an opioid antagonist since 1994. 7 The most common use of naloxone is for the treatment of opioid overdose in both hospital and out-patient settings, and in rapid detoxification (being given intravenously [i.v.] when combined with other medications). 2 Other routes of administration

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review

192. Opioid Management Practices for the Prevention of Drug Diversion and Misuse: A Review of the Clinical Evidence and Guidelines

overdose, injection drug use and poly drug use. 2 Opioid diversion signifies any instance where drugs are re-routed from their lawful purpose at any point in the pharmaceutical manufacturing and distribution process. 3 For example, opioids can be diverted in the preclinical stages through theft at plants, in transit or at pharmacies. Opioids can also be diverted during the post-clinical phase by sharing, selling and misusing of prescribed medications or by stealing medications. 3 Opioid misuse can (...) on their patterns of item response Class 1 (use a prescribed) (n= 4,973 [18.9%]) Class 2 (prescribed misusers) (n= 7079[ 26.9]) Class 3 (medically healthy abusers) (n=9420)[ 35.8%]) Class 4 (Illicit users) (n=4842) [18.4]) Cross class comparisons and pairwise comparison were all statistically significant (p<.05) Class 1 use as prescribed were characterized by a general lack of problematic drug use- including non- medical prescription opioid use Class 2 exhibited similar medical problems to those using

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review

193. A Complicated Case of Triple Valve Infective Endocarditis in an IV Drug User with a Bicuspid Aortic Valve Requiring Three Separate Salvage Operations: A Case Report and Literature Review Full Text available with Trip Pro

(methicillin sensitive Staphylococcus aureus) IE in a young adult male with a past medical history of bicuspid aortic valve and IV drug abuse. His clinical course was complicated by aortic valve destruction and development of third-degree AV block, as well as an aorto-left atrial fistula requiring emergent operation for AV replacement and patch repair. The patient required two reoperations for recurrent endocarditis and its complications. (...) fatal. Diagnosing IE can be straightforward in patients with the typical oslerian manifestations such as bacteremia, evidence of active valvulitis, peripheral emboli, and immunologic vascular phenomena. In the acute course, however, the classic peripheral stigmata may be few or absent, particularly among intravenous drug abuse (IVDA) patients in whom IE is often due to a S. aureus infection of right-sided heart valves. We present a complicated case of a very aggressive native aortic valve MSSA

2015 Case reports in cardiology

194. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment

weight risk (Roffeei et al., 2014). These genetic factors associated with drug-induced weight gain and its metabolic consequences provide clues as to the underlying mechanisms, and in the future may provide opportu- nities for personalised medicine in the predictive assessment of metabolic risk with antipsychotic drug treatment. Antipsychotic medications and diabetes. One aspect of the metabolic pathology of schizophrenia is a two-fold increase in diabetes. The aetiology of this is complex (...) substance use, abuse or dependence, 6 Journal of Psychopharmacology because it has been reported to reduce substance use and improve psychosis, but the supporting data are still preliminary (D). | | Specific medication for relapse prevention in patients with alcohol dependence should be considered, such as naltrexone or acamprosate (D). Management of the increased risks for diabetes and CVD The management of the medical consequences of weight gain and obesity should be in primary care. Initial

2016 British Association for Psychopharmacology

195. Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations

/treatment Phase Stage IV Cancer Drug: apatinib Phase 4 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 217 participants Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Other Official Title: A Clinical Study Investigating Adverse Drug Reactions and Their Biomarker Correlations in Stage IV Cancer Patients Following Individualized Therapy of Apatinib Actual Study Start Date : February 26, 2018 (...) Estimated Primary Completion Date : December 2019 Estimated Study Completion Date : December 2019 Resource links provided by the National Library of Medicine related topics: resources: Arms and Interventions Go to Arm Intervention/treatment single group Drug: apatinib Patients with advanced (stage IV) gastric cancer, non-small-cell lung cancer (NSCLC), breast cancer or ovarian cancer will be included in this study to receive apatinib treaetment starting from 250 mg Qd and closely monitored for ADRs

2018 Clinical Trials

196. Break the Cycle: Prevention for Reducing Initiation Into Injection Drug Use

See Sponsor: Icahn School of Medicine at Mount Sinai Collaborators: University of Tartu National Institute on Drug Abuse (NIDA) Information provided by (Responsible Party): Icahn School of Medicine at Mount Sinai Study Details Study Description Go to Brief Summary: Break the Cycle is a two-session, one-on-one, in-person intervention study designed to reduce the role persons who inject drugs (PWID) play initiating non-PWID into injection drug use. Study implementation is at two sites: New York City (...) Intervention/treatment Phase Substance Abuse, Intravenous Prevention and Control Behavioral: Break the Cycle Intervention Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 400 participants Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Other Official Title: Break the Cycle: Adapting Break the Cycle to Reduce Initiation Into Injecting Drug Use in Tallinn, Estonia and New York City

2018 Clinical Trials

197. A Safety and Tolerability Study of RJX Drug Product in Healthy Participants

compatible with this study; Have received an investigational product within the last 3 months; Have suspected allergies to RJX, related compounds, or any components of the formulation, or history of significant atopy; Regularly use known drugs of abuse and/or show positive findings on drug screening or Day -1; Are women who are pregnant, intend to become pregnant, or are lactating; Participants will be excluded for using any of the following medication: aspirin, multivitamins/vitamins or mineral (...) preparations within 14 days prior to investigational product administration or 24 hours post the last infusion; prescription, herbal or over the counter medications within 14 days of investigational product administration, with the exception of: simple analgesics such as paracetamol, excluding aspirin oral non-steroidal anti-inflammatory drugs thyroid treatment, estrogen replacement therapy hormonal contraception Statins and anti-hypertensives are permitted for elderly participants in Cohort 6 (Part 1

2018 Clinical Trials

198. Drug Interaction Study of CT1812 in Healthy Volunteers

therapy within 2 weeks prior to administration of the first dose of any study-related treatment. This exclusion is extended to 4 weeks for any drugs known to induce or inhibit hepatic drug metabolism. Consumption of alcohol within 14 days prior to dose administration or during any in-patient period A positive urine drug screen including ethanol, cocaine, THC, barbiturates, amphetamines, benzodiazepines, and opiates Any history of alcohol abuse, illicit drug use, significant mental illness, physical (...) dependence to any opioid within the past two years, or any history of drug abuse or addiction within the past two years A history of difficulty with donating blood Donated whole blood within 45 days or blood products within 7 days prior to enrollment. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its

2018 Clinical Trials

199. Hepatitis C in Injection-Drug Users — A Hidden Danger of the Opioid Epidemic Full Text available with Trip Pro

Analgesics, Opioid Drug Users Epidemics Hepatitis C etiology Humans Opioid-Related Disorders complications epidemiology Substance Abuse, Intravenous complications 2018 3 31 6 0 2018 3 31 6 0 2018 6 21 6 0 ppublish 29601263 10.1056/NEJMp1716871 PMC5993680 NIHMS972424 JAMA. 2016 Jul 12;316(2):191-210 27404187 Drug Alcohol Depend. 2017 Feb 1;171:39-49 28013096 MMWR Morb Mortal Wkly Rep. 2017 May 12;66(18):470-473 28493860 Am J Public Health. 2018 Feb;108(2):175-181 29267061 Lancet Gastroenterol Hepatol (...) Hepatitis C in Injection-Drug Users — A Hidden Danger of the Opioid Epidemic 29601263 2018 06 20 2018 11 14 1533-4406 378 13 2018 03 29 The New England journal of medicine N. Engl. J. Med. Hepatitis C in Injection-Drug Users - A Hidden Danger of the Opioid Epidemic. 1169-1171 10.1056/NEJMp1716871 Liang T Jake TJ From the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD (T.J.L.); and the Centers for Disease Control and Prevention

2018 The New England journal of medicine

200. A Clinical Study of PD-L1 Antibody ZKAB001(Drug Code) in Limited Stage of High-grade Osteosarcoma

by the National Library of Medicine resources: Arms and Interventions Go to Arm Intervention/treatment Experimental: ZKAB001 5 mg/kg/time Three or six patients will treated with the dose of 5 mg/kg/time of ZKAB001 IV bi-weekly. DLT was observed within 28 days after administration. Drug: ZKAB001 5mg/kg 5mg/kg/times bi-week IV administration of ZKAB001 Other Name: PD-L1 monoclonal antibody Experimental: ZKAB001 10 mg/kg/time Three or six patients will treated with the dose of 10 mg/kg/time of ZKAB001 IV bi (...) on T lymphocytes and other cells of the immune system) administered every 14 days in subjects with limited stage of high-grade osteosarcoma of maintenance therapy after adjuvant chemotherapy. Condition or disease Intervention/treatment Phase Osteosarcoma Drug: ZKAB001 5mg/kg Drug: ZKAB001 10mg/kg Drug: ZKAB001 15mg/kg Phase 1 Phase 2 Detailed Description: The study will consist of 4 periods: Screening (up to 28 days), Lead-in period (Day -28), Treatment (up to 24 cycles or 1 year, whichever occurs

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>